Related Experiment Videos
María de Los Ángeles Salgado-Jiménez1, Juan Villagómez-Méndez2, Baltazar Joanico-Morales3
1Clínica de VIH del Hospital Vicente Guerrero. Acapulco, Guerrero, México. ansaji83@hotmail.com.
Salud Publica De Mexico
|January 31, 2022
Summary
People with human immunodeficiency virus (HIV) on specific antiretroviral (ARV) therapy may have a reduced risk of contracting or being hospitalized for COVID-19. This Spanish cohort study offers insights into managing COVID-19 in HIV-positive populations.
Area of Science:
- Infectious Diseases
- Virology
- Public Health
Background:
- The COVID-19 pandemic presents unique challenges for individuals with pre-existing conditions, including human immunodeficiency virus (HIV).
- Understanding the interaction between SARS-CoV-2 (the virus causing COVID-19) and HIV is crucial for patient management and public health strategies.
Purpose of the Study:
- To investigate the potential impact of specific antiretroviral (ARV) therapies on the risk of COVID-19 infection and hospitalization in an HIV-positive cohort.
- To generate knowledge regarding the health outcomes of HIV-positive individuals during the COVID-19 pandemic.
Main Methods:
- Observational study of a Spanish cohort.
- Analysis of COVID-19 incidence and hospitalization rates among individuals receiving specific antiretroviral treatments.
Main Results:
- Administration of specific antiretroviral (ARV) agents was associated with a lower risk of developing COVID-19.
- Patients on these ARVs also showed a reduced risk of hospitalization due to COVID-19.
Conclusions:
- Specific antiretroviral (ARV) therapies may offer a protective effect against COVID-19 infection and severe outcomes in people living with HIV (PLWH).
- Further research is warranted to elucidate the mechanisms behind this observed association and to inform clinical guidelines for PLWH during viral pandemics.